Regeneron Raises Sales Forecast on Demand for Top Drug Eylea

Regeneron Pharmaceuticals Inc. surged the most in almost a year in New York trading after raising the sales forecast for its leading drug and beating analysts’ estimates for revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.